Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care.
Type
Public
HQ
Dublin, US
Founded
1983
Size (employees)
22 (est)-60%
Navidea Biopharmaceuticals was founded in 1983 and is headquartered in Dublin, US
Report incorrect company information

Key People/Management at Navidea Biopharmaceuticals

Michael Goldberg

Michael Goldberg

President and Chief Executive Officer

Navidea Biopharmaceuticals Office Locations

Navidea Biopharmaceuticals has an office in Dublin
Dublin, US (HQ)
5600 Blazer Parkway,
Show all (1)
Report incorrect company information

Navidea Biopharmaceuticals Financials and Metrics

Navidea Biopharmaceuticals Revenue

Embed Graph
Navidea Biopharmaceuticals's revenue was reported to be $1.81 m in FY, 2017
USD

Revenue (Q1, 2018)

276.4 k

Gross profit (Q1, 2018)

276.1 k

Gross profit margin (Q1, 2018), %

99.9%

Net income (Q1, 2018)

(6.7 m)

EBIT (Q1, 2018)

(2.5 m)

Market capitalization (11-Jul-2018)

34.4 m

Closing share price (11-Jul-2018)

0.2

Cash (31-Mar-2018)

817 k

EV

38.2 m
Navidea Biopharmaceuticals's current market capitalization is $34.4 m.
Annual
USDFY, 2016FY, 2017

Revenue

22 m1.8 m

Cost of goods sold

2.3 m3.7 k

Gross profit

19.7 m1.8 m

Gross profit Margin, %

90%100%
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

1.1 m2.3 m2.1 m2.9 m4 m4.7 m5.4 m8.5 m580 k276.4 k

Cost of goods sold

270.5 k807.9 k449.1 k332.7 k457.6 k534.9 k560.7 k921.8 k318

Gross profit

804.2 k1.4 m1.7 m2.5 m3.5 m4.2 m4.8 m7.6 m580 k276.1 k

Gross profit Margin, %

75%64%79%88%89%89%90%89%100%100%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.9 m5.5 m7.2 m1.5 m2.8 m

Accounts Receivable

1.2 m816.5 k

Inventories

2.2 m1.5 m

Current Assets

37.3 m8.6 m12.6 m10.8 m13.8 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

17.5 m10.4 m4.9 m15.8 m11.4 m5.5 m1.2 m810.4 k13.4 m817 k

Accounts Receivable

487.1 k1.5 m1.2 m1.8 m1.9 m

Inventories

1.9 m1.1 m571.6 k1.2 m877.2 k898.9 k769.8 k804.9 k748

Current Assets

20.6 m14 m8 m19.5 m15 m10 m6.9 m9.4 m21.7 m16.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(42.7 m)(35.7 m)(27.6 m)(14.3 m)74.9 m

Inventories

(1.9 m)761 k136 k(861.3 k)1.5 m

Accounts Payable

1 m(944.9 k)290 k5.4 m(6 m)

Cash From Operating Activities

(35.6 m)(29.1 m)(19.1 m)3.6 m59.1 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(22 m)(28.9 m)(7.3 m)(17 m)(25.1 m)(3.7 m)(10.4 m)(10.4 m)85.6 m(6.7 m)

Depreciation and Amortization

235.4 k360.7 k149.8 k299.1 k431.4 k149.6 k267.4 k378.8 k86.5 k38 k

Inventories

326.7 k573.2 k240.5 k(355.5 k)(83.7 k)(246 k)(116.9 k)(195.3 k)1.5 m

Accounts Payable

(748.3 k)(45.4 k)428.5 k(119.8 k)(178.6 k)1.1 m3.4 m3.2 m(3.8 m)(154.8 k)
USDY, 2018

EV/EBIT

-15.3 x

EV/CFO

-16.9 x

Revenue/Employee

12.6 k

Financial Leverage

3.7 x
Show all financial metrics
Report incorrect company information

Navidea Biopharmaceuticals News and Updates

Report incorrect company information

Navidea Biopharmaceuticals Company Life and Culture

Report incorrect company information